UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE

Pharmaceuticals (Basel, Switzerland), 2021-12, Vol.14 (12), p.1265

2021

Link zum Volltext

Verfügbarkeit prüfen

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals

Cancers, 2022-02, Vol.14 (5), p.1172

2022

Link zum Volltext

Verfügbarkeit prüfen

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists

Pharmaceuticals (Basel, Switzerland), 2023-04, Vol.16 (5), p.674

2023

Link zum Volltext

Verfügbarkeit prüfen

Radiolabeled Bombesin Analogs

Cancers, 2021-11, Vol.13 (22), p.5766

2021

Link zum Volltext

Verfügbarkeit prüfen

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT

Journal of Nuclear Medicine, 2010-07, Vol.51 (7), p.1059-1067

2010

Link zum Volltext

Verfügbarkeit prüfen

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Journal of translational medicine, 2023-09, Vol.21 (1), p.1-604, Article 604

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5

Molecules (Basel, Switzerland), 2020-09, Vol.25 (18), p.4155

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours

Pharmaceuticals (Basel, Switzerland), 2022-08, Vol.15 (9), p.1085

2022

Link zum Volltext

Verfügbarkeit prüfen

Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers

Journal of Nuclear Medicine, 2016-08, Vol.57 (8), p.1282-1288

2016

Link zum Volltext

Verfügbarkeit prüfen

A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

EJNMMI research, 2020-08, Vol.10 (1), p.90-90, Article 90

2020

Link zum Volltext

Verfügbarkeit prüfen

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

EJNMMI research, 2024-04, Vol.14 (1), p.37-37

2024

Link zum Volltext

Verfügbarkeit prüfen

SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers

Pharmaceuticals (Basel, Switzerland), 2021-03, Vol.14 (4), p.300

2021

Link zum Volltext

Verfügbarkeit prüfen

Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

Pharmaceuticals (Basel, Switzerland), 2020-12, Vol.14 (1), p.19

2020

Link zum Volltext

Verfügbarkeit prüfen

Design and development of the theranostic pair 177 Lu-OPS201/ 68 Ga-OPS202 for targeting somatostatin receptor expressing tumors

Journal of labelled compounds & radiopharmaceuticals, 2019-08, Vol.62 (10), p.635-645

2019

Link zum Volltext

Verfügbarkeit prüfen

Bombesin-Targeted PET of Prostate Cancer

Journal of Nuclear Medicine, 2016-10, Vol.57 (Suppl 3), p.67S-72S

2016

Link zum Volltext

Verfügbarkeit prüfen

PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference

The Journal of nuclear medicine (1978), 2011-07, Vol.52 (7), p.1110-1118

2011

Link zum Volltext

Verfügbarkeit prüfen

Hybrid Bombesin Analogues: Combining an Agonist and an Antagonist in Defined Distances for Optimized Tumor Targeting

Journal of the American Chemical Society, 2013-11, Vol.135 (45), p.16793-16796

2013

Link zum Volltext

Verfügbarkeit prüfen

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

European journal of nuclear medicine and molecular imaging, 2023-08, Vol.50 (10), p.3050-3061

2023

Link zum Volltext

Verfügbarkeit prüfen

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

Journal of medicinal chemistry, 2023-07, Vol.66 (13), p.8484-8497

2023

Link zum Volltext

Verfügbarkeit prüfen

P-69 - New bicyclic somatostatin receptor agonists for imaging and therapy of neuroendocrine neoplasia

Nuclear medicine and biology, 2022-11, Vol.114-115, p.S66-S67

2022

Link zum Volltext

Verfügbarkeit prüfen

Design and development of the theranostic pair 177Lu‐OPS201/68Ga‐OPS202 for targeting somatostatin receptor expressing tumors

Journal of labelled compounds & radiopharmaceuticals, 2019-08, Vol.62 (10), p.635-645

2019

Link zum Volltext

Verfügbarkeit prüfen

Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours

European journal of nuclear medicine and molecular imaging, 2011, Vol.38 (1), p.97-107

2011

Link zum Volltext

Verfügbarkeit prüfen

Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors

Journal of Nuclear Medicine, 2011-12, Vol.52 (12), p.1970-1978

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin

Journal of Nuclear Medicine, 2013-05, Vol.54 (5), p.762-769

2013

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides

Clinical cancer research, 2009-08, Vol.15 (16), p.5240-5249

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(68)

Sprache

Englisch
(68)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(32)
Humans
(29)
Animals
(25)
Tumors
(21)
Mice
(19)
Peptides
(18)
Cell Line, Tumor
(13)
Nuclear Medicine
(13)
Oncology
(13)
Radiology, Nuclear Medicine & Medical Imaging
(12)
Tissue Distribution
(12)
Female
(11)
Imaging
(10)
Male
(10)
Pharmacology & Pharmacy
(10)
Prostate Cancer
(10)
Radiology
(10)
Medicine
(9)
Medicine & Public Health
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists

Radiolabeled Bombesin Analogs

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours

Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers

A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers

Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

Design and development of the theranostic pair 177 Lu-OPS201/ 68 Ga-OPS202 for targeting somatostatin receptor expressing tumors

Bombesin-Targeted PET of Prostate Cancer

PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference

Hybrid Bombesin Analogues: Combining an Agonist and an Antagonist in Defined Distances for Optimized Tumor Targeting

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

P-69 - New bicyclic somatostatin receptor agonists for imaging and therapy of neuroendocrine neoplasia

Design and development of the theranostic pair 177Lu‐OPS201/68Ga‐OPS202 for targeting somatostatin receptor expressing tumors

Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours

Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors

Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin

Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides

Suchergebnisse filtern